	US 12,338,279 B2
	Selective and potent inhibitory antibodies of myostatin activation
Christopher Chapron, Cambridge, MA (US); Frederick C. Streich, Jr., Cambridge, MA (US); Kaleigh Canonico, Cambridge, MA (US); Shaun M. Cote, Cambridge, MA (US); Francis Danehy, Jr., Cambridge, MA (US); Melissa Fulham, Cambridge, MA (US); Yan Huang, Cambridge, MA (US); Justin William Jackson, Cambridge, MA (US); Mania Kavosi, Cambridge, MA (US); and Sandeep Kumar, Cambridge, MA (US)
Assigned to Scholar Rock, Inc., Cambridge, MA (US)
Filed by SCHOLAR ROCK, INC., Cambridge, MA (US)
Filed on Dec. 19, 2024, as Appl. No. 18/988,612.
Application 18/988,612 is a continuation of application No. PCT/US2023/085574, filed on Dec. 21, 2023.
Claims priority of provisional application 63/588,081, filed on Oct. 5, 2023.
Claims priority of provisional application 63/515,267, filed on Jul. 24, 2023.
Claims priority of provisional application 63/477,552, filed on Dec. 28, 2022.
Claims priority of provisional application 63/476,908, filed on Dec. 22, 2022.
Prior Publication US 2025/0122274 A1, Apr. 17, 2025
Int. Cl. C07K 16/22 (2006.01); A61K 9/00 (2006.01); A61K 31/155 (2006.01); A61K 38/26 (2006.01); A61K 39/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01)

CPC C07K 16/22 (2013.01) [A61K 9/0019 (2013.01); A61K 31/155 (2013.01); A61K 38/26 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01)]

11 Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to pro/latent myostatin, wherein the antibody or antigen-binding fragment comprises six complementarity determining regions (CDRs), an H-CDR1, an H-CDR2, an H-CDR3, an L-CDR1, an L-CDR2, and an L-CDR3, wherein:

a) the H-CDR1 comprises the amino acid sequence of SEQ ID NO: 201, the H-CDR2 comprises the amino acid sequence of SEQ ID NO: 219, the H-CDR3 comprises the amino acid sequence of SEQ ID NO: 220, the L-CDR1 comprises the amino acid sequence of SEQ ID NO: 216, the L-CDR2 comprises the amino acid sequence of SEQ ID NO: 222, and the L-CDR3 comprises the amino acid sequence of SEQ ID NO: 223, wherein the CDR sequences are numbered according to Kabat numbering system;

b) the H-CDR1 comprises the amino acid sequence of SEQ ID NO: 234, the H-CDR2 comprises the amino acid sequence of SEQ ID NO: 235, the H-CDR3 comprises the amino acid sequence of SEQ ID NO: 236, the L-CDR1 comprises the amino acid sequence of SEQ ID NO: 237, the L-CDR2 comprises the amino acid sequence EVS, and the L-CDR3 comprises the amino acid sequence of SEQ ID NO: 239, wherein the CDR sequences are numbered according to Chothia numbering system; or

c) the H-CDR1 comprises the amino acid sequence of SEQ ID NO: 3, the H-CDR2 comprises the amino acid sequence of SEQ ID NO: 256, the H-CDR3 comprises the amino acid sequence of SEQ ID NO: 257, the L-CDR1 comprises the amino acid sequence of SEQ ID NO: 258, the L-CDR2 comprises the amino acid sequence EVS, and the L-CDR3 comprises the amino acid sequence of SEQ ID NO: 260, wherein the CDR sequences are numbered according to IMGT numbering system.